Loading
A phase 3 trial testing A166 in HER2-positive breast cancer, active and no longer recruiting.
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy is a phase 3 interventional study registered as NCT06968585, led by Sichuan Kelun-Biotech Biopharmaceutical, and active but no longer recruiting on the registry. Official title: A Phase III,Multicenter,Randomised,Open-Label,Active-Controlled Trial of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy. Planned enrolment is 365 participants (actual). The study started in 2023-07-18 and primary completion is expected in 2026-11-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/